Galapagos

AbbVie, Galapagos to co-develop cystic fibrosis therapies

Wednesday, September 25, 2013 12:24 PM

Galapagos and AbbVie have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide.

More... »

AbbVie and Galapagos extend GLPG0634 collaboration

Monday, June 10, 2013 11:39 AM

Galapagos, which specialized in novel modes-of-action, and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a phase II program in Crohn's, designed to facilitate rapid progression into phase III.  Upon successful completion of the study, expected in the second quarter of 2015, AbbVie will pay Galapagos $50 million. 

More... »

Galapagos and Roche conclude strategic alliance

Monday, March 11, 2013 10:38 AM

Galapagos, mid-size clinical stage biotechnology company, has agreed with Roche to end their alliance in fibrosis. Roche will make a payment of $975,000 to Galapagos for work completed in 2012, contributing to 2012 group revenues.

More... »

Galapagos acquires Cangenix

Wednesday, January 16, 2013 11:21 AM

Galapagos, a mid-size clinical stage biotechnology company, has acquired Cangenix, a gene-to-structure biotech company, to add structure-based drug discovery to its Argenta service offering. Cangenix's state-of-the-art technology will augment Argenta's ability to design new drugs and fill a growing client need.

More... »

Galapagos subsidiary BioFocus collaborates with Ono on CNS drug discovery

Tuesday, September 4, 2012 12:46 PM

Galapagos’ service division BioFocus and Ono Pharmaceutical have signed a new collaboration agreement focused on discovering novel drugs for CNS disorders. BioFocus will use its drug discovery platform to deliver leads and clinical candidates.

More... »

AstraZeneca, BioFocus, Argenta collaborate on respiratory and inflammatory diseases

Thursday, March 15, 2012 06:02 AM

Galapagos’ service companies, BioFocus and Argenta, have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets in respiratory and inflammatory diseases.

More... »

Almirall and Galapagos enter into research alliance

Friday, January 27, 2012 01:57 PM

Barcelona, Spain-basedAlmirall has formed a research alliance with BioFocus, an affiliate of Galapagos. The three-year collaboration is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. 

More... »